The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial results

By sjmartinez • November 2, 2023

Rugo HS, Im SA, Joy AA, Shparyk Y, Walshe JM, Sleckman B, Loi S, Theall KP, Kim S, Huang X, Bananis E, Mahtani R, Finn RS, Diéras V. The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial results. Future Oncol. 2023 Nov 2. doi: 10.2217/fon-2023-0407. Epub ahead of print. PMID: 37916267.

Tags: Advanced breast cancer, Endocrine therapy, Hematology/Oncology, HR+/HER2–, lay summary, Palbociclib, plain language summary, Publications

Pregnancy and breast cancer in young women: current updates and future directions

Zhang S, Guclu SB, Lipsyc-Sharf M, Kapoor NS. Pregnancy and breast cancer in young women: current updates and future directions. Ther Adv Med Oncol. 2025[...]

Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma

Falchi L, Sureda A, Leppä S, Vermaat JS, Nijland M, Christensen JH, de Vos S, Holte H, Merryman RW, Lugtenburg PJ, Abrisqueta P, Linton K,[...]

Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study

Patnaik MM, Ali H, Wang ES, Yacoub A, Foran JM, Gupta V, Schiller GJ, Stevens DA, Talpaz M, Wall S, Lasho TL, Mangaonkar AA, Badar[...]